Artigo de periodico

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study (2018)

• Authors:
  • Robak, Tadeusz
  • Jin, Jie
  • Pylypenko, Halyna
  • Verhoef, Gregor
  • Siritanaratkul, Noppadol
  • Drach, Johannes
  • Raderer, Markus
  • Mayer, Jiri
  • Pereira, Juliana
  • Tumyan, Gayane
• Autor USP: PEREIRA, JULIANA - FM
• Unidade: FM
• DOI: 10.1016/S1470-2045(18)30685-5
• Subjects: LINFOMA; IMUNOTERAPIA; ESTUDOS RANDOMIZADOS; ANTINEOPLÁSICOS
• Agências de fomento:
  • Janssen Research Development
• Language: Inglês
• Imprenta:
  • Publisher place: New York
  • Date published: 2018
• Source:
  • Título: Lancet oncology
  • ISSN: 1470-2045
  • Volume/Número/Paginação/Ano: v. 19, n. 11, p. 1449-1458, 2018

Informações sobre o DOI: 10.1016/S1470-2045(18)30685-5 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo NÃO é de acesso aberto
  
• Cor do Acesso Aberto: closed

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  ROBAK, Tadeusz et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, v. 19, n. 11, p. 1449-1458, 2018Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30685-5. Acesso em: 12 jan. 2026.

• APA

  Robak, T., Jin, J., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Drach, J., et al. (2018). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, 19( 11), 1449-1458. doi:10.1016/S1470-2045(18)30685-5

• NLM

  Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2026 jan. 12 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5

• Vancouver

  Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2026 jan. 12 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study
• A difficult case of angioimmunoblastic T-cell lymphoma to diagnose
• Estudo de células precuroras em leucemias agudas: identificação e fator de prognóstico das proteínas Bcl-2, Bax e CD95/Fas/APO-1
• Panoramic and skull imaging may aid in the identification of multiple myeloma lesions
• Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates
• Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
• Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University
• Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
• Disseminated histoplasmosis and erythrophagocytosis in an immunocompromised host. [Editorial]: the role of bone marrow evaluation for prompt diagnosis of invasive fungal infections
• Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma